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ABSTRACT 
Kinin formation by H ageman factor activation of plasma kallikrein was tudied 
in fifteen patient with various kin di ease.· . No diff renee wa found between pla rna 
taken before and after t reatment with betametha one 1.5 to 3.5 mg per day through 
fourte n day . Time curve w re performed on plasma from four of the patien t ' . The 
activation rate were identical before and after betamethasone treatment. 
In vitro addit ion of cort isol, final concentrations from 2.7 X 10-e to 11.9 X 10-
5 M, 
gave no significant difference in kinin formation by Hageman factor act ivation of 
plasma kallikr in from normal human pla rna. 
Kinin., which produce pain, increased vascu-
lar perm ability and vasodilation, have been 
on id red to be mediators of inflammation (1, 
2). Large amounts of kallikrein , kinin-fo rminO' 
cnzym , xi t in inactive form in pla. rna, and 
may be activated by H ageman facto r . I t has 
b n proposed (3) t hat glucocorticoids rna~· 
act in part by preventing interaction between 
activated kallikrein and its sub t rate. The pres-
ent tudic. w re undertaken to determine if 
cr\u oeorticoid m therapeutic do ages prevent 
or dccrensc kinin formation in human plasma. 
J\1A'l'ERIAL A TD METHODS 
Fift. '<'n paLien t , aged 29 to 76 year . suffe ring 
from nt ri ou kin di:sca ·rs (Tabl , I) w re st udied. 
40 n1l b lood wn coll<·etcd in polypropylene tube::; 
conLainin~ 4 ml 3.2 p r c nt sodium citrate. 
prior to and nHcr four! 'CD d ays of treatment wi t h 
bet a met IJHsonc. Pia ma wa sepnr,tlcd in t he same 
tub . . r<' l1lo \·ed wi lh si liconized pipcltrs. and 
froz ·n at - 20° C un til i mmediat ly befo re incuba-
tion. 4.5 ml pla ·nw was preincubatcd for 10 minute ~ 
with 0 .6 ml 2.62 X w-~ M EDTA and 1.5 ml 0 .5 M 
p hosphat<' buff!'l' pH 6. 30 mg Cdile no . 545 (me h 
30-80) W <h' I h n added and incubated aL 37° C for 
60 minull' . EDTA is n potent kinina. e inhibitor 
(4). eli iC' is n dintomnerou sili ca p roduct whieh 
uetivntC'' H agC' man fa<·tor. In prrliminary ~:>t uclic 
(5) it wa:-~ ·hown that maximum a mount of 
kinins w r ' obtain d a ft •r 45 minut in!'ubation . 
and that 4 DT in mild a id ·ompl tcly inhibi ted 
plu m a kininu . Th incubation"· were to1 JJ<:>cl by 
upport d by a grant from thr 
ani h t at R arch F unda tion. 
Pr f'n t d in part at the F enno- candinaYian 
.vmpo~ium on Pia makinin in H I inki, J anua rY. 
1 69. . 
R eeive Augu t 22. 1969; accepted for publica-
tion ptE'mber 25 1969. 
* Fr m t h D epartm n of D ermatologv. Rirr -
ho pit , Uni,· r it.y of op nhag n . · 
adding three volumes of boiling absolute alcohol , 
boilP-d for 4 minutes. prepared for assay . and a -
say ed on t he estrus rat u terus according to a 
proccdur<' pre \·iousb · d escribed (2). Pl asma from 
four palient was incubated for 120 minutes. and 
'amplC' were withdrawn for kinin determination at 
ntrious intervals from 0 .5 lo 120 minutes. The 
dosage of betametbasone is indicated in Table I. 
Pl asma kinin formation by H ageman factor 
net i ,·a bon was also studied on even samples of 
no rmal human plasma wi th and wi thout cortisol 
added. Tlw final concen t ration of cor tisol was 2.7 
X 10-u M. On t hree of the seven samples incuba-
t ion1' W<' re also performed wi th a cor tisol concen-
trat ion of 5.4 X 10-o M. In two of the experiments 
glas ·· powde r was u cd instead of Celite . In t hree 
ot her (• xperiments " ·ith corti ol concentration. 
from 4.8 X 10-5 to 11.9 X 10-5 M no EDT A was 
added and pho phate h uffer pH 6 was sub-
:-;til u ted with 0 .5 M pho 'phate b uffer pH 7.4. Th ese 
in!'uhations were carried out for 20 minutes and 
·amp1f'::; wNe withdrawn fo r kinin determination 
at \·ari ous in tcrntl ' from 0.5 to 20 minute . Corti ol 
\\T:- p reincuhnted wi th the pla rna from 10 to 60 
minute:-; bdorr ad i,·ation. 
.\ll ~Z:lnsswarp was C'a r -fully ilil'onizcd before u~->e . 
RESULT 
The data ummarized in T able I how t hat 
treatment " ·ith betametha one in normal 
thern peu tic dosage through fourteen days does 
not reduce the amount of kinjn formed by 
Cclite activation of kallikrein in mild acid. The 
pH of t he final buffer/ pla"ma mixture was 6.6. 
Table I include the data on amounts of kinin 
found in the tudy, where pla rna fraction 
were inv tiga ted at variou interval during 
incubation. Time cur eN demonstrating the re-
~ult of thi part of the tudy can be een in 
Figur 1. No difference in activation rate wa 
found after teroid treatment. Neither did the 
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TABLE I 
Plasma kinins measured in 1,..5 ml plasma incubated at 37° C. with 30 1ng Celite after preinc1tbation with 
0.6 ml2 .62 X 1o-2 M EDTA and 1.5 ml 0.5 M phosphate buffer pH 6. 'The plasma was from 15 patients 
su.ffering f rom various skin diseases and treated with betamelhasone through fourteen days. Determination 
prior to and after treatment. 
Dosage in mg/ day m,ug kinins formed per ml p lasma 
ex/ Age Diagnosis 
I week 2 week Before treatment 
F / 52 P yoderma gangreno urn 2 .0 2.0 574 
M/ 66 Pyoderma gangrenosum 3.0 3.0 401 
l\1/ 56 E rythroderma 2.0 2.0 296 
F / 76 Erythroderma 1.5 1.5 226 
M / 67 Erythroderma 2 .0 1.5 4 6 
F / 56 Pustula r bacterid of palms 2 .0 1.5 416 
and soles 
F / 41 Pus t ular psoriasis 2.0 1.5 360 
M/ 71 Mycosis fungoides 2.0 1.5 20 
:vi/ 60 Mb. H odgkin 2.5 3.5 343 
M / 61 Photodermatitis 2.0 1.5 590 
M/51 Contact dermatitis 2 .0 1.5 431 
l\1/ 48 Contact dermatitis 2 .0 1.5 463 
M / 36 Contact dermat itis 2.0 1.5 3GO 
F / 60 Drug eruption 2.0 1.5 568 
F / 29 Recurrent erysipelas* 2.0 1.5 400 
Mean± S .E. 40 ± 30 
*This patient received systemic treatment with penicillin s imul talleou ly . 
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FIG. 1. Formation of kinin in human plasma by Celit activation of kallikrein expre ·· ed 
in per cent of maximum amounts of kinins. formed; mean of four analy ~ of pla~ma fmm 
four patients before and after treatment w1th betamethasone. 30 mg Ceh te wa · mcubated 
with 4.5 ml plasma at 37° C for 120 minutes after 10 minutes preincubation with 0.6 ml 
2.62 X 10-2 M EDT A and 1.5 ml 0.5 M phosphate buffer pH 6. 
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in vitro tudies with and without cortisol added 
to normal human plasma (Tables II and III) 
show ignificant differences in amounts of 
kinin formed or rate of kinin formation by 
Hageman factor activation of plasma kallikrein. 
DISCUSSION 
The re ults of this study are in accordance 
with the data of Eisen, Greenbaum and Lewis 
(6). They found that lcinin formation occurred 
norman~ in plasma taken from two patients re-
('f'JVmg betamethasonc and one receiving pred-
TABLE II 
Plasma kinins measured in 3 ml plasma incubated 
at 37° C for 60 minutes with 20 mg Celite after 
pre£ncubalion for 10 minutes with 0.4 ml 2 .62 X 
10- 2 M ED'TA and 1 ml 05 M phosphate buffer 
pl-1 6 with and without cortisol added. 'The con-
centrations of cortisol indicated are final con-
centrations 
m_~.~g kinins formed per ml plasma 
No. of experiment Plasma Plasma with with 
Plasma a lone corti sol cortiso 1 
(2.7 X 10-a M ) (5.4 X 
I0-6 M ) 
1 391 40-! 413 
2 319 331 385 
3 541 451 538 
4 440 428 
5 -!19 41G 
(i* 319 334 
I 7* 325 3-±~ 
---- -----
11can ± R.E . 1 393 ± 31 I 38 ± 18 I 
* Act,ivution by glass powder instead of Celite . 
nisone. Our data are not in agreement with the 
results of Cline and Melmon (3). We found no 
evidence that normal therapeutic dosages of 
steroids prevent interaction between activated 
kallikrein and its substrate. The activation 
rates as well as the maximum amounts of 
kinins formed before and after treatment were 
identical. Cline and Melmon used an indirect 
technique measuring results of Hageman factor 
and leukocyte activation by difference in total 
kininogen concentration before and after ac-
t ivation. It remains to be proven that this dif-
ference represents kinin formation. In our 
studies the amounts of kinins formed through 
Hageman activation were measured directly. 
\¥ e were able to do this by eliminating destruc-
tion by kininase. Hageman factor activation of 
plasma kallikrein leads to formation of the 
relea able fraction of kininogen, kininogen II 
(7) or the so-called compound B of Margolis 
( ) . This fraction probably takes part in the 
early stages of the inflammatory process. 
The study of Cline and Melmon (3) was per-
formed at pH 7.4, and we studied patient 
plasma at r>H 6.6. An acid pH was chosen be-
cause of the acid pH found in inflammation (9). 
The slightly acid pH also contributes to an ac-
cumulation of kinins by reduction of kallikrein 
inhibitor (10) as well as by a reduction in 
kininase activity (11, 12) . If steroids potentiate 
these factors the discrepancies could be ex-
plained. However, in our in vitro studies at 
ncu tral pH, no differences 'vere found between 
time ClHYes from cortisol and non-cortisol 
treated plasma. This part of the study was per-
formed with a high concentration of cortisol. 
TABLE III 
Plasma. kinins measured i n 3 ml plasma 1'ncubated at 37° C with 25 mg Celite after preincubation with 2 
ml 0 .5 AI phosphate buj}'er pH 7.4 with and without co'rtisol added. The concentrations of cortisol indicated 
are final concentrations. The preincubation time was 10 minutes in experiment 1 and60 minutes in experi-
ments 2 and 3. 
m.ug kinins formed per ml plasma 
No. of Cortisol cone. 1:) 
experiment 
0 ntin. 0.5 min. 1.5 min . 3 min. 5 min. 10 min . 20 min. 
1 0 0 156 423 195 111 28 0 
1 4. X w-s 0 106 400 186 1 3 39 0 
2 0 0 37 299 340 320 203 59 
2 11.9 X w-5 0 10 179 282 281 204 65 
3 0 0 49 246 264 313 105 0 
3 11.9 X 10- 6 0 46 237 284 254 102 0 
~ 
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